Multiple sclerosis - From probable to definite diagnosis: A 7-year prospective study

Archives of Neurology

Volumn 57, Issue 7, 2000, Pages 974-979

  Achiron, Anat ^a   Barak, Yoram ^b  

^a SHEBA MEDICAL CENTER   (Israel)

^b ABARBANEL MENTAL HEALTH CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SURVIVAL;

EID: 0033924203     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.57.7.974     Document Type: Article

References (31)

1. Patzold U, Pocklington PR. Course of multiple sclerosis: first results of a prospective study carried out on 102 MS patients from 1976-80. Acta Neurol Scand. 1982;65:248-266.
2. Paty DW. Magnetic resonance in multiple sclerosis. Curr Opin Neurol Neurosurg. 1993;6:202-208.
3. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 1994;44:635-641.
4. Poser S, Wikstrom J, Bauer HJ. Clinical data and identification of special forms of multiple sclerosis with a standardized documentation system. J Neurol Sci. 1979;40:159-168.
5. Amor S, O'Neill JK, Morris MM, et al. Encephalitogenic epitopes of myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein for experimental allergic encephalomyelitis induction in Biozzi ABH (H-2Ag7) mice share an amino acid motif. J Immunol. 1996;156:3000-3008.
6. Olsson T, Sun J, Hillert J, et al. Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis. Eur J Immunol. 1992; 22:1083-1087.
7. Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med. 1996;183:1777-1788.
8. Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum. 1997;40:1374-1382.
9. Lehmann PV, Sercarz EE, Forsthuber T, Dayan CM, Gammon G. Determinant spreading and the dynamics of the autoimmune T-cell repertoire. Immunol Today. 1993;14:203-208.
10. Mor F, Cohen IR. Shifts in the epitopes of myelin basic protein recognized by Lewis rat T-cells before, during, and after the induction of experimental autoimmune encephalomyelitis. J Clin Invest. 1993;92:2199-2206.
11. European Charcot Foundation Working Group for Treatment Trials. Guidelines for early treatment trials in patients presenting with clinical and paraclinical abnormalities which put them at high risk for conversion to multiple sclerosis. Mult Scler. 1995:1(suppl 1):S55-S59.
12. Alexander L, Berkeley AW, Alexander AM. Prognosis and treatment of multiple sclerosis: quantitative nosometric study in multiple sclerosis. JAMA. 1958;166: 1943-1949.
13. Kurtzke JF, Beebe GW, Nagler B, Auth TL, Kurland LT, Nefzger MD. Studies on the natural history of multiple sclerosis: correlates of clinical change in an early bout. Acta Neurol Scand. 1973;49:379-395.
14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13:227-231.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33:1444-1452.
16. Munschauer FE III, Stuart WH. Rationale for early treatment with Interferon beta-1a in relapsing-remitting multiple sclerosis. Clin Ther. 1997;19:868-882.
17. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the Optic Neuritis Treatment Trial. Neurology. 1997;49:1404-1413.
18. Beck RW, Cleary PA, Trobe JD, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis: the Optic Neuritis Study Group. N Engl J Med. 1993;329:1764-1769.
19. McAlpine D. The benign form of multiple sclerosis: a study based on 241 cases seen within three years of onset and followed up until the tenth year or more of the disease. Brain. 1961;84:186-203.
20. Muller R. Studies in disseminated sclerosis. Acta Med Scand. 1949;133(suppl 222):1-214.
21. Adams DK, Sutherland JM, Fletcher WB. Early clinical manifestations of disseminated sclerosis. BMJ. 1950;2:431-436.
22. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS: a 10-year follow-up. Brain. 1998; 121:495-503.
23. Soderstrom M, Ya-Ping J, Hillert J, Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology. 1998;50:708-714.
24. Paolino E, Fainardi E, Ruppi P, et al. A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996;60:572-575.
25. Morrissey SP, Miller DH, Kendall BE, et al. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically Isolated syndromes suggestive of multiple sclerosis: a 5-year follow-up study. Brain. 1993; 116:135-146.
26. Lee KH, Hashimoto SA, Hooge JP, et al. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 1991;41:657-660.
27. Trojano M, Avolio C, Manzari C, et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry. 1995;58:300-306.
28. Miller DH, Hornabrook RW, Purdie G. The natural history of multiple sclerosis: a regional study with some longitudinal data. J Neurol Neurosurg Psychiatry. 1992; 55:341-346.
29. Visscher BR, Liu KS, Clark VA, Detels R, Malmgren RM, Dudley JP. Onset symptoms as predictors of mortality and disability in multiple sclerosis. Acta Neurol Scand. 1984;70:321-328.
30. McRae BL, Vanderlugt CL, Dal Canto MC, Miller SD. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J Exp Med. 1995;182:75-85.
31. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 1990;346:183-187.